PolyPid (PYPD) Income towards Parent Company (2019 - 2026)
PolyPid (PYPD) posted Income towards Parent Company of $7.7 million for Q1 2026, down 10.5% sequentially from $8.6 million in Q4 2025, and down 6.28% YoY from $8.2 million in Q1 2025.
PolyPid (PYPD) Income towards Parent Company (2019 - 2026) Analysis & Trends
PolyPid has reported Income towards Parent Company for 8 years, with the latest figure at $7.7 million in Q1 2026.
- Quarterly Income towards Parent Company fell 6.28% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.6 million (up 9.4% YoY) and the FY2025 annual result came in at -$34.2 million, down 17.73% from the prior year.
- Income towards Parent Company declined to $7.7 million in Q1 2026 per PYPD's latest filing, from $8.6 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $11.9 million in Q1 2022 and troughed at $5.6 million in Q3 2023.
- A 5-year average of $7.9 million and a median of $7.7 million in 2024 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 265.25% in 2022, down 51.2% in 2022.
- Over 5 years, Income towards Parent Company stood at $6.5 million in 2022, then decreased by 1.84% to $6.3 million in 2023, then surged by 34.02% to $8.5 million in 2024, then climbed by 1.66% to $8.6 million in 2025, then retreated by 10.5% to $7.7 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $7.7 million, $8.6 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.30 Mn |
| Mar 31, 2026 | 7.73 Mn |
| Dec 31, 2025 | 8.64 Mn |
| Sep 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | 9.87 Mn |
| Mar 31, 2025 | 8.25 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Sep 30, 2024 | 7.72 Mn |
| Jun 30, 2024 | 6.29 Mn |
| Mar 31, 2024 | 6.43 Mn |
| Dec 31, 2023 | 6.34 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 5.82 Mn |
| Mar 31, 2023 | 6.02 Mn |
| Dec 31, 2022 | 6.46 Mn |
| Sep 30, 2022 | 9.12 Mn |
| Jun 30, 2022 | 11.85 Mn |
| Mar 31, 2022 | 11.87 Mn |
| Dec 31, 2021 | 13.23 Mn |
| Sep 30, 2021 | 9.94 Mn |